News

Explore insights from SDPA leaders Renata Block, DMSc, MMS, PA-C, and Sarah Vicari, MMS, PA-C, on mentorship, volunteerism, and fostering growth for PAs.

Findings suggest immune dysregulation and chronic inflammation in atopic dermatitis may contribute to increased skin cancer susceptibility.

ORKA-001 by Oruka Therapeutics offers promising yearly dosing for psoriasis, showcasing extended efficacy and safety in early clinical trials.

What exciting sessions and updates are you looking forward to at the SDPA Fall 2025 Conference in San Antonio? Click here to answer our poll and let us know!

An AI-powered handheld spectroscopy device is showing promise in improving melanoma detection accuracy among primary care physicians, addressing critical gaps in early diagnosis and timely referral.

The FDA issued 18 warning letters to websites illegally selling unapproved and misbranded botulinum toxin products, citing serious safety risks including botulism-related adverse events.

Clinical trials DELTA 1, 2, 3, and DELTA FORCE demonstrated significant improvements in CHE severity and patient-reported outcomes with delgocitinib.

Preview the SDPA Fall 2025 conference in San Antonio for 4 days of networking, education, and expert-led sessions for dermatology PAs.

A phase 2 extension trial found roflumilast foam safe and effective for up to 52 weeks in patients with moderate to severe seborrheic dermatitis.

Skin pain in atopic dermatitis significantly impacts quality of life, necessitating its recognition and treatment as a vital symptom for better patient outcomes.

Explore the latest FDA approvals in dermatology, including treatments for eczema and psoriasis, and gain insights on chronic spontaneous urticaria.

At the 10th Annual Symposium on Hidradenitis Suppurativa Advances, Ralph George, MD, FRCS, emphasized that the growing collaboration between medical and surgical management is redefining the role of procedures in HS.

Allergan Aesthetics pioneers regenerative skincare through secretome science, enhancing skin health with fibroblast-derived exosomes for transformative results.

Lindsay Ackerman, MD, explains the importance of transparency when prescribing medications with boxed warnings.

Incyte launches Ingenuity Awards to empower HS community, funding innovative patient-driven initiatives for better treatment and outcomes in hidradenitis suppurativa.

Castle Biosciences’ new test uses molecular signatures from lesional skin to guide systemic therapy decisions in moderate to severe AD.

Discover how Prithwiraj Maitra, PhD, advances skin care innovation with exosomes, emphasizing scientific validation and ingredient transparency in cosmetic formulations.

From acne to psoriasis, nutrition influences disease severity, treatment response, and patient quality of life.

Explore innovative acne management strategies from James Del Rosso, DO, focusing on personalized treatments and patient education for effective results in diverse cases.

Phio Pharmaceuticals reveals promising results for PH-762, a novel siRNA therapy targeting skin cancer, showcasing effective tumor clearance and safety.

New findings from LEO Pharma reveal chronic hand eczema affects 1 in 10 adults, highlighting the need for improved recognition and management in dermatology.

Advances in atopic dermatitis research could bring longer-lasting biologics and improved treatment adherence.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about upadacitinib for vitiligo, the commercial release of roflumilast for pediatric AD, a recap of the top pearls at Fall Clinical 2025, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Discover the latest advancements in atopic dermatitis treatment and patient advocacy during Eczema Awareness Month, shaping future care and quality of life.

UCB reveals three-year data on bimekizumab, showcasing significant pain relief and lesion resolution in hidradenitis suppurativa patients at the 2025 SHSA.

Christopher Bunick, MD, PhD, emphasizes how dermatologists can improve outcomes through vigilant skin exams and collaborative care with oncology teams.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.